Project Grant F31DA062434
- This Project Grant award from the National Institute on Drug Abuse (CFDA 93.279 - Drug Use and Addiction Research Programs) provides $702,965 to the University of Texas Health Science Center at Houston to conduct a pilot mechanistic study on repurposing the drug semaglutide for the treatment of cocaine use disorder. The study aims to provide proof-of-concept evidence that semaglutide, a glucagon-like peptide receptor agonist, can modulate key reward-related mechanisms underlying cocaine use,...
- This Project Grant award of $400,000, funded by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research conducted by Iontx Inc. to advance the development of a novel small-molecule compound targeting the FGF13/NAV1.6 complex for the treatment of cocaine use disorder (CUD). The key objectives of this 12-month project are to: 1) conduct structure-activity relationship (SAR) analysis and optimization of the lead compound...
- This Project Grant award of $405,230 from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), supports research to advance NR4A1 as a novel target for treating cocaine use disorder. The key objectives are to: 1) Synthesize and screen derivatives of the NR4A1 agonist Cytosporone B to identify lead compounds, and 2) Establish milestones towards filing a commercially-viable Investigational New Drug (IND) application for an NR4A1-targeted...
- This Project Grant award for $440,000, provided by the National Institute on Drug Abuse (NIDA) under the Drug Use and Addiction Research Programs (CFDA 93.279), aims to investigate the therapeutic potential of the G protein-coupled receptor GPR6 as a novel target for treating cocaine use disorder. The key objectives include: 1) examining GPR6 expression in specific neuron subpopulations involved in cocaine reward processing, 2) evaluating GPR6 status following intravenous self-administration...
- This $319,547 project grant awarded on September 15, 2023 by the National Institute on Drug Abuse (NIDA) under the Drug Abuse and Addiction Research Programs (CFDA 93.279) supports Afasci, Inc.'s research and development of a novel treatment for cocaine use disorder (CUD). The project will investigate the effects of Afasci's investigational new drug AFA-281, which inhibits both the T-type Cav3 ion channels and soluble epoxide hydrolase, on reducing cocaine-seeking behavior and hyperlocomotion in...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, under the Drug Use and Addiction Research Programs (CFDA 93.279), will provide $474,347 to Wake Forest University Health Sciences (WFUHS) to investigate the impact of nicotine and alcohol co-use on the abuse potential of cocaine in monkey models. The goal is to extend the study of cocaine misuse to include the co-use of nicotine and/or alcohol, examining behavioral and...
- This Project Grant award from the National Institute on Drug Abuse (NIDA), under the Drug Use and Addiction Research Programs (CFDA 93.279), provides $877,500 to the University of California, San Diego (UCSD) to investigate pre-existing differences in GABAergic and glutamatergic transmission within the central amygdala (CEA) of rats and their potential contribution to individual differences in cocaine addiction susceptibility. The study employs a novel method called RATTACA to predict high and...
- This federal Project Grant award of $758,218 from the National Institute on Drug Abuse (NIDA), part of the Drug Use and Addiction Research Programs (CFDA 93.279), supports research on the potential of nociceptin/orphanin FQ peptide (NOP) receptors as targets for novel pharmacotherapies to treat cocaine use disorder (CUD) in non-human primate models. The key products and services to be delivered under this award include: Examining how NOP receptors influence vulnerability to developing CUD...
- This $480,000 Project Grant award from the National Institute on Drug Abuse (NIDA), under the federal Drug Use and Addiction Research Programs (CFDA 93.279), aims to develop new tools to facilitate the study of how drugs of abuse interact with G protein-coupled receptors (GPCRs) and alter their signaling. The key products and services to be delivered under this 5-year grant include: Generation of chemical biology tools to enable time-resolved cryogenic electron microscopy imaging of GPCR...
- The National Institute on Drug Abuse (NIDA) awarded a $643,019 Cooperative Agreement to Virginia Commonwealth University (VCU) under the Drug Use and Addiction Research Programs (CFDA 93.279) to explore the potential efficacy and safety of psilocybin as a treatment for cocaine use disorder (COCUD). The project aims to conduct a proof-of-concept randomized controlled trial to evaluate the safety, tolerability, and potential efficacy of psilocybin combined with psychedelic integrative therapy...
MUSCARINIC RECEPTOR MEDIATION OF COCAINE-DEPENDENT REWARD SIGNALS: IMPACT OF PHARMACOLOGICAL MODULATION - PROJECT SUMMARY STIMULANT USE DISORDER (SUD), DEFINED AS THE PATTERNED USE/ABUSE OF PSYCHOSTIMULANTS SUCH AS COCAINE, METHAMPHETAMINE, OR PRESCRIBED AMPHETAMINES, IS AN EPIDEMIC THAT DIRECTLY AFFECTS AROUND 2.5 MILLION PEOPLE IN THE UNITED STATES. CURRENTLY, THERE ARE NO FDA-APPROVED PHARMACOTHERAPIES FOR SUD. SIGNALING THROUGH THE NEUROTRANSMITTER DOPAMINE (DA) IN THE MESOLIMBIC CIRCUIT BRAIN REGIONS, THE NUCLEUS ACCUMBENS (NAC) AND VENTRAL TEGMENTAL AREA (VTA), IS NECESSARY FOR THE MAINTENANCE OF SUD. MUSCARINIC ACETYLCHOLINE RECEPTORS (MACHRS) IN THE NAC HAVE BEEN SHOWN TO MODULATE THE DOPAMINERGIC TONE IN THE REGION AND DECREASE COCAINE PREFERENCE IN RATS. OF THE FIVE SUBTYPES OF MACHR, THE M1 AND M4 RECEPTORS SHOW PROMISE AS PHARMACOLOGICAL TARGETS FOR THE TREATMENT OF SUD. THESE TWO RECEPTORS ARE LOCATED ON THE DENDRITIC SPINES OF MEDIUM SPINY NEURONS (MSNS) WITHIN THE NAC AND ARE FED BY INPUTS FROM CHOLINERGIC INTERNEURONS (CINS). MSNS ARE PROJECTION NEURONS CONTAINING EITHER D1 OR D2 DA RECEPTORS, WHICH MEDIATE THE DIRECT (REWARD) AND INDIRECT (AVERSION) REWARD PATHWAYS, RESPECTIVELY. PREVIOUSLY, THE MODULATION OF MACHR ACTIVITY HAS BEEN SHOWN TO REDUCE COCAINE CHOICE IN RODENTS. THE M1-PREFERRING AGONIST XANOMELINE, FOR EXAMPLE, HAS BEEN SHOWN TO LOWER PREFERENCE FOR COCAINE IN RODENTS. HOWEVER, NOT ONLY DOES THIS PRODUCE UNDESIRABLE PERIPHERAL SIDE EFFECTS, THE HIGHLY CONSERVED ORTHOSTERIC BINDING SITE MAKES SUBTYPE-SELECTIVITY DIFFICULT. ALLOSTERIC MODULATORS OF MACHRS EFFECTIVELY SOLVE BOTH PROBLEMS AND COULD PROVE VALUABLE FOR THE TREATMENT OF SUD THROUGH ATTENUATION OF COCAINE-DEPENDENT INCREASES IN DA SIGNALING IN THE NAC. TWO MACHR PAMS, THE M4- SELECTIVE VU0152100 AND VU0364572, HAVE BOTH BEEN SHOWN TO REDUCE COCAINE PREFERENCE IN A DRUG VERSUS NON-DRUG REINFORCER ASSAY AND TO REDUCE DA IN THE NAC USING MICRODIALYSIS. HERE THE FOLLOWING HYPOTHESIS IS PROPOSED: ADMINISTRATION OF MACHR-SELECTIVE COMPOUNDS WILL REDUCE COCAINE-DEPENDENT INCREASES IN REWARD SIGNALING BY MODULATING M1 AND M4 MACHRS LOCATED ON MSNS IN THE NAC. AIM 1 WILL DETERMINE THE ABILITY OF THESE TWO COMPOUNDS TO REDUCE THE COCAINE-DEPENDENT ALTERATIONS IN DA LEVELS AND DYNAMICS IN THE NAC USING FIBER PHOTOMETRY WITH THE GRABDA FLUORESCENT LABEL FOR DA ACTIVITY. AIM 2 WILL EXPLORE THE DIFFERENTIAL ROLE THAT MACHR MODULATION MAY HAVE ON CA2+ SIGNALING D1- AND D2-CONTAINING MSNS USING FIBER PHOTOMETRY ON D1- AND D2-CRE RATS.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $44.2k | 7/12/25 |